COPENHAGEN (Reuters) -Obesity drugmaker Novo Nordisk on Wednesday cut its full-year sales and profit outlook amid lacklustre ...

Novo Nordisk (NYSE:NVO) trimmed its full-year 2025 sales and profit forecast on Wednesday, citing weaker-than-expected U.S.

The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.